CADTH review: Antithrombotic therapy for patients with atrial fibrillation

Source: Canadian Agency for Drugs and Technologies in Health (CADTH) Area: News The Canadian Agency for Drugs and Technologies in Health (CADTH) has published a review addressing the use of novel oral anticoagulants (NOAC) and antiplatelet agents for the management of patients with atrial fibrillation (AF). Evidence-informed recommendations were developed to address the following policy questions:   . In AF patients with a lower risk of stroke (CHADS2 score < 2), which antithrombotic therapy is optimal? . In AF patients with a higher risk of stroke (CHADS2 score ? 2) who are unable to achieve adequate anticoagulation with warfarin, i.e., whose time in therapeutic range (TTR) is < 66%, which NOAC is optimal?   The review concludes that: . NOACs should be considered for the prevention of stroke for patients with non-valvular AF and who have a CHADS2 score ? 1, and who are unable to readily achieve adequate anticoagulation with warfarin. . If a decision is made to use a NOAC, selection should be based ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news